Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. SEPN
SEPN logo

SEPN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Septerna Inc (SEPN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
25.170
1 Day change
0.12%
52 Week Range
32.630
Analysis Updated At
2026/03/13
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Septerna Inc (SEPN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown promising revenue growth and positive analyst sentiment, the technical indicators suggest a neutral trend, and insider selling raises concerns. Additionally, no immediate proprietary trading signals or significant catalysts warrant an urgent buy decision.

Technical Analysis

The MACD is negative and expanding, RSI is neutral at 34.565, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 27.883, with key support at 25.943 and resistance at 29.824.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
6

Positive Catalysts

  • Analysts have raised price targets, with the most recent target at $40, reflecting confidence in the company's pipeline.

  • Q4 revenue increased by 11950% YoY, surpassing expectations.

  • Upcoming Phase 1 readout of SEP-631 in 2026 is a potential long-term catalyst.

Neutral/Negative Catalysts

  • Insider selling has increased significantly (1608.82% over the last month).

  • The MACD and RSI indicate no bullish momentum.

  • No recent congress trading data or proprietary trading signals to support an immediate buy.

Financial Performance

In Q4 2025, revenue grew significantly by 11276.42% YoY to $24.1 million, but net income dropped by 48.05% YoY to -$10.74 million, and EPS declined by 61.90% YoY to -$0.24. Gross margin remained strong at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain a Buy rating with raised price targets, reflecting confidence in the company's pipeline and potential market opportunities. The highest price target is $43, with a focus on SEP-631 and SEP-479 as key growth drivers.

Wall Street analysts forecast SEPN stock price to rise
8 Analyst Rating
Wall Street analysts forecast SEPN stock price to rise
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.140
sliders
Low
25
Averages
33.14
High
43
Current: 25.140
sliders
Low
25
Averages
33.14
High
43
Truist
Srikripa Devarakonda
Buy
maintain
$34 -> $35
AI Analysis
2026-03-11
Reason
Truist
Srikripa Devarakonda
Price Target
$34 -> $35
AI Analysis
2026-03-11
maintain
Buy
Reason
Truist analyst Srikripa Devarakonda raised the firm's price target on Septerna to $35 from $34 and keeps a Buy rating on the shares. The firm is incrementally positive on the company after its Q4 update, where clinical trial timelines remain on track, the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$35 -> $40
2026-03-02
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$35 -> $40
2026-03-02
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Septerna to $40 from $35 and keeps a Buy rating on the shares after the company presented data from the Phase 1 trial of SEP-631 for the treatment of chronic spontaneous urticaria and other mast cell-driven diseases. The firm's raised target reflects an increase in its view of the probability of approval for SEP-631 to 35% from the prior 30% given the positive Phase 1 data.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SEPN
Unlock Now

People Also Watch